Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
Mieke Van Hemelrijck(Ghent University Hospital), Michael Fahey, Prokar Dasgupta(King's College London), Caroline M. Moore(University College London Hospitals NHS Foundation Trust), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Lui S. Lee(Singapore General Hospital), Bruce J. Trock(Johns Hopkins University), Christopher P. Filson(Emory University), Behfar Ehdaie(NewYork–Presbyterian Hospital), Anders Bjartell(Lund University), J. Rubio‐Briones, Byung Ha Chung, Jonas Hugosson(Sahlgrenska University Hospital), Daan Nieboer(Erasmus MC), Vincent J. Gnanapragasam(Addenbrooke's Hospital), Todd M. Morgan(University of Michigan), Jozien Helleman(Erasmus MC), Jeri Kim(The University of Texas MD Anderson Cancer Center), Lee Lui Shiong(Singapore General Hospital), Kenneth Muir(Manchester Academic Health Science Centre), Antti Rannikko(Royal Free London NHS Foundation Trust), Monique J. Roobol(Erasmus MC), Tim Hulsen(Philips (Netherlands)), Arnauld Villers(Université de Lille), Peter R. Carroll(University of California, San Francisco), Theodorus van der Kwast(Erasmus MC), Mark Frydenberg(Monash University), Lukas Hefermehl, Tom Pickles, Henk Obbink, Cees de Jonge, Artitaya Lophatananon(Manchester Academic Health Science Centre), Laurence Klotz(University of Toronto), Antoinette S. Perry, Yoshiyuki Kakehi(Kagawa University), Ji Xi(Cleveland Clinic), Wim van der Linden(Philips (Netherlands)), Eric Hyndman, Chris H. Bangma(Erasmus MC), Xinge Ji(Cleveland Clinic), R. Valdagni
Cited by 93
Related Papers
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
BioVenn – a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams
|BMC Genomics|2008|1.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k